Nexalin Technology, Inc. (NXL)
NASDAQ: NXL · IEX Real-Time Price · USD
1.510
-0.150 (-9.04%)
At close: Jul 2, 2024, 4:00 PM
1.470
-0.040 (-2.65%)
After-hours: Jul 2, 2024, 7:58 PM EDT
Nexalin Technology Revenue
Nexalin Technology had revenue of $158.86K in the twelve months ending March 31, 2024, down -84.56% year-over-year. Revenue in the quarter ending March 31, 2024 was $78.67K with 157.43% year-over-year growth. In the year 2023, Nexalin Technology had annual revenue of $110.75K, a decrease of -91.62%.
Revenue (ttm)
$158.86K
Revenue Growth
-84.56%
P/S Ratio
72.11
Revenue / Employee
$26,477
Employees
6
Market Cap
11.46M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 110.75K | -1.21M | -91.62% |
Dec 31, 2022 | 1.32M | 1.18M | 817.20% |
Dec 31, 2021 | 144.07K | -98.85K | -40.69% |
Dec 31, 2020 | 242.91K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionNXL News
- 1 day ago - Nexalin Technology Announces Closing of $5.2 Million Public Offering - GlobeNewsWire
- 5 days ago - Nexalin Technology Announces Pricing of $5.2 Million Public Offering - GlobeNewsWire
- 12 days ago - Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Alzheimer's and Dementia - GlobeNewsWire
- 18 days ago - Nexalin Technology and VolitionRX Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Accesswire
- 19 days ago - Nexalin Technology Announces Regulatory Approval to Sell Nexalin's Gen-2, 15 mA Neurostimulation Device by the Brazilian Health Regulatory Agency (Anvisa) - GlobeNewsWire
- 4 weeks ago - Nexalin Technology to Present at the Spring MicroCap Rodeo Conference on June 6th - GlobeNewsWire
- 4 weeks ago - FDA Provides Feedback and Reaches Consensus on Nexalin's Design for Planned Anxiety and Insomnia Clinical Studies of its Gen-3 HALO Clarity™ Headset Device - GlobeNewsWire
- 5 weeks ago - Nexalin America Selected to Join the National Traumatic Brain Injury Registry Coalition to Propel TBI Awareness and Research Efforts - GlobeNewsWire